Inclusion Criteria:  History of paroxysmal atrial fibrillation (per 2019 HRS guidelines definition: an episode of AF that terminates spontaneously or with intervention in less than seven days), according to current guideline indications for paroxysmal AF CA (Class I/II); or patients with history of persistent atrial fibrillation (per 2019 HRS guidelines definition: sustained AF episode lasting more than 7 days, but less than 1 year), according to current guideline indications for persistent AF CA (Class I/IIIa) any time in the past. 50 years of age or older at time of consent CHA2DS2-VASc ≥ 2 in men or ≥ 3 in women at the time of consent CA to be performed for AF for the first time as standard of care within 1 calendar month after consent and prior to randomization date Confirm Rx™ ICM or other FDA-approved Abbott ICM device indicated for monitoring symptoms after CA as standard of care and inserted within 1 calendar month after consent and prior to randomization date  Exclusion Criteria:  Inability or unwilling to undergo CA (e.g., presence of intra-cardiac thrombus, contraindication to anticoagulation or other contraindication to CA) Inability or unwilling to undergo Confirm Rx™ ICM or other FDA-approved Abbott ICM device insertion Inability to tolerate any AAD therapy Sustained atrial fibrillation lasting more than 3 years prior to date of consent Left atrial diameter of 60 mm or greater Unsuccessful Confirm Rx™ ICM or other FDA-approved Abbott ICM device insertion NYHA class IV congestive heart failure Patients with an implantable cardiac rhythm device (ICD/CRTD/PPM) LV ejection fraction ≤ 35% without a CIED, but indicated for an ICD/CRT-D Coronary revascularization or valve surgery within 3 calendar months prior to date of consent Prior valve surgery using a mechanical prosthesis anytime in past Life expectancy <1 year after consent date for any medical condition Pregnancy or nursing Unwillingness to comply with all post-procedural follow-up requirements and to sign informed consent